Celularity (CELU) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$19.0M

Revenue (quarter)

$3.8M

Revenue growth (year over year)

−66.34%

Gross profit (trailing twelve months)

$998,000.00

Gross margin

5.26%

Net income (trailing twelve months)

−$71.1M

Net income (quarter)

$874,000.00

Net income growth (year over year)

+104.42%

Net margin

−374.74%

Return on equity

—

EPS (trailing twelve months)

−$2.73

Book value per share

−$1.21

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

135.45%

Payout ratio

—

Dividend yield

—

Company profile

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

• Is Celularity (CELU) profitable?

  No. Celularity reported a net loss of $71.1M over the trailing twelve months.

• How much revenue does Celularity (CELU) make?

  Celularity generated $19.0M in revenue over the trailing twelve months, down 66.34% year over year.

• How do I buy stock in Celularity (CELU)?

  CELU trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.